35
DAFTAR PUSTAKA
1. Mann D, Chakinala M. Heart failure: Pathopysiology and diagnosis. In Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison’s Principle of Internal Medicine. 19th
Ed. Mc Graw Hill Education. 2015. p.1500-1506
2. Yancy Clyde W, Jessup Mariell, Bozkurt Biykem, Drazner MH, Fonarow GC, Geraci SA,et al. ACCF/AHA 2013 Guideline for the Management of Heart Failure, A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines .Circulation. 2013;128:e240-e327.
3. Roger Veronique L. Epidemiology of Heart Failure. Circ Res. 2013;113:646-659 4.Siswanto Bambang B, Hersunarti Nani, Erwinanto, Barack R, Pratikto RS,
Nauli SE, Lubis AC. Pedoman tatalaksana gagal jantung, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2015, edisi pertama; 1
5. Rouf Rossane. Heart Failure. The John Hopkins Internal Medicine and Board review. 4th ed. Chapter 6 : 49-54
6.Kementrian kesehatan Republik Indonesia. Situasi kesehatan jantung.
http://www.depkes.go.id/article/view/15021800003/situasi-kesehatan-jantung.html (diakses 20 Januari 2015).
7.Tendera M. Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe. European Heart Journal Supplements 2005: 7 (Supplement J), J5–J9
8. Greene S, Fonarow G, Vaduganathan M, Khan S, Butler J, Gheorgidae M. The vulnerable phase after hospitalization for heart failure. Nature reviews cardiology 2015; 14:1-10
9. Cámara A, Vales J, Tapia P, Esteban E, Fernández S, Sandubete E, et al. Role of biological and non biological factors in congestive heart failure mortality: PREDICE-SCORE: A clinical prediction rule. Cardiology Journal 2012, 19, 578–585
10. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005;95(suppl):8B-13B
11. Levine B, Kalman J, Mayer L, Fillit H.M, Packer M; Elevated circulating levels of tumor necrosis factor in severe heart failure. N Engl J Med. 323 1990:236-241
12. Gullestad L, Ueland T, Vinge LE, Vincent A, Yndestat A, Aukurst P. Inflammatory cytokines in heart failure : mediators and marker. Cardiology 2012;122:23–35
13. Clearfield MB. C-Reactive Protein : A New risk assessment tool for cardiovascular disease. JAOA. 2005 ; 105 : 409-416
14. Gottdiener John S, Polak Joseph F, Arnold AM, Aurigemma GP, Tracy RP, et al. Predictors of Congestive Heart Failure in the Elderly: The Cardiovascular Health Study J Am Coll Cardiol 2000;35:1628–37
15. Anand Inder S, Latini Roberto, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-Reactive Protein in Heart Failure Prognostic Value and the Effect of Valsartan. Circulation. 2005; 112:1428-1434
36
16. Huang WP, Yin WH, Jn HL, Chiang MC, Feng AN, Young MS. C-reactive protein levels in chronic congestive heart failure. Acta Cardioll Sin. 2004;20:7-14
17. Panggabean M. Gagal Jantung. Dalam : Setiati S, Alwi I, Sudoyo, Syam AF, AW, Simadibrata M, Setyohadi B. Buku Ajar Ilmu Penyakit Dalam. PDUI 2014. Edisi VI, BAB 18. Interna Publishing. hal 1132-35
18. Vikramsyah R, Lilly M. Pathophysiology of Heart Disease : A Collaborative Project of Medical Students and Faculty. 4th ed. Baltimore-Philadelpia. Lippincott Williams & Wilkins, 225-245.
19. Black Steven, Kushner Irving, Samols David. C-Reactive Protein. The Journal of Biological Chemistry. 2004; 279:48487-90
20. Aguiar FJ, Junior MF, Sales MM, Cruz-Neto LM, Foncesa LA, Sumita NM,et al. C-reactive protein : clinical applications and proposals for a rational use. REV ASSOC MED BRAS. 2013;59(1):85-92
21. Shrivastava AK, Singh HV, Razaida A, Singh SK. C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart Journal. 2015;67:89-97
22. Epaminondas Zakynthinos, Nikolitsa Pappa. Inflammatory biomarkers in coronary artery disease. Journal of Cardiology. 2009; 53: 317-33
23. John Danesh and Mark B. Pepys. C-Reactive Protein and Coronary Disease: Is There a Causal Link? Circulation. 2009; 120: 2036-39
24. Eleni S. Nakou, Evangelos N. Liberopoulos et al. The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview. Current Vascular Pharmacology. 2008; 6: 258-70
25. Oikonomou Evangelos, Tousoulis Dimitris, Siasos G, Zaromitidou M, Papavasiliou AG, Stefandis C. The role of inflammation in heart failure: New therapeutic approaches. Hellenic J Cardiol 2011;52:30-40
26. Huang WP, Yin WH, Jen HL, Ching MC, Feng AN, Young MS. C-reactive protein levels in chronic congestive heart failure. Acta Cardioll Sin 2004;20:7-14
27. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243–249
28. Galal Haitham, Awad Omar, Samir A, Selim R. Prognostic value of plasma levels of high sensitivity C-reactive protein in chronic systolic heart failure of ischemic origin. Heart mirror J. 2013;7(2); 123-128
29. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Young MS et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004; 147(5):931-8.
30. ozda , rta , Kiliç T, Acar E, Agir A, Sahin T, et al. Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure. Med Sci Monit 2010; 16(3):CR156-61
31. Alonso Martínez JL, Llorente Diez B, Echegaray Agara M, Preciado O, Echezaretta MU, Arencibia G. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002; 4(3):331-6
32. Maisel A, Xue Y, Shah K, Mueller C, Nowark R, Peacock W,et al. Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study. Circ Heart Fail. 2011;4:613-620
37
33. Roger VL, Weston SA, Redfield MM, Homan J, Killian J, Yawn B et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292: 344–50.
34. Loehr LR, Rosamond WD, Chang PP, Folsom A, Chambless L. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101:1016–22.
35. Bueno H, Ross JS, Wang Y, Chen J, Vidan M, Normand SL et al. Trends in length of stay and short-term out- comes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA. 2010;303:2141–7.
36. Chugh S, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M et al. Epidemiology of sudden cardiac death: clinical and research implications.
Prog Cardiovasc Dis. 2008;51:213–228.
37. Lloyd-Jones D, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB et al. Heart disease and stroke statistics 2010 update: a report from the American Heart Association. Circulation 2010;121:e46–e215.
38. Ho K, Pnsky J, Kanel W, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol. 1993;22(4s1):A6-A13
39. Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: a contemporary population-based perspective. Arch Intern Med 2007;167:490–496
40. Dharmarajan K, Hasieh A, Lin Z, Bueno H, Ross J, Horwitz L et al.
Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355–363. 41. Desai, A. S. & Stevenson, L. W. Rehospitalization for heart failure: predict or
prevent? Circulation 126, 501–506 (2012).
42. Chun, S. Tu J, Wijeysundera H, Austin P, Wang S, Levy D. et al. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ. Heart Fail 2012; 5: 414–421
43. Gheorghiade M, Pang P, Ambrosy A, Lan G, Schmidt P, Fillipato G et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail. Rev 2012; 17, 485–509.
44. Zile, MR, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008;118, 1433–1441.
45. Adamson PB, Magalski A, Braunscweight F, Bohm M, Reynolds D, Steinhasu D
et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J. Am. Coll. Cardiol. 2003;41, 565–571.
46. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1:91–97.
47. Velavan P, Khan NK, Goode K, Rigby AS, Loh PH, Komajda M et al. Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. International Journal of Cardiology 2010; 138: 63–69 48. North B, Sinclair D. The intersection between aging and cardiovascular
disease. Circ Res. 2012;110:1097-1108.
38
49. Lakatta E, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises, part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107:139 –146.
50. Strait J, Lakatta E. Aging associated cardiovascular changes and their relation to heart failure. Heart Fail Clin. 2012; 8(1): 143–164
51. Gustafsson F, Pedersen C, Seibæk M, Burchardt H, Kober L for the DIAMOND study group. Effect of age on short and long-term mortality in patients admitted to hospital with congestive heart failure. European Heart Journal 2004; 25, 1711–17
52. Suwaidi J, Asaad N, Al-Qahtani A, El-Menyar A, Al-Mulla A, Singh R et al. Effect of Age on Outcome on Patients Hospitalized With Heart Failure: From a 20-Year Registry in a Middle-Eastern Country (1991–2010). Congest Heart Fail. 2012;18:320–326
53. Martínez-Sellés M, García Robles JA, Prieto L, Frades E, Munoz R, Castro OD, et al. Hospitalized Congestive Heart Failure Patients with Preserved versus Abnormal Left Ventricular Systolic Function. Rev Esp Cardiol, 2002; 55: 579–586
54. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of clinical model. JAMA, 2003; 290: 2581–2587.
55. Hillege HL, Nitsch D, Pfeffer M, Swedberg K, McMurray JJ, Yusuf S, et al. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcomes in a broad spectrum of patients with heart failure. Circu- lation, 2006; 113: 671–678.
56. Brophy JM, Dagenais GR, McSherry F, Williford W, Yusuf SA. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med, 2004; 116: 300–304.
57. Kalogeropoulos AP, Tang WHW, Hsu A, Felker GM, hernandez AF, Troughton RW, et al. High-Sensitivity C-reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac failure,2014;20(5):1-8
58. Windram JD, Loh PH, Rigby AS, Hanning I, Clarck A, Cleland JG. Relationship of hight-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. American heart journal, 2007;153(6): 1048-1055
59. Kozdag G, Ertas G, Kilic T, Acar E, Agir A, Sahin T, et al. Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure. Med Sci Monit,2010; 16(3) :156-161
60. Zhu L, Zou Y, Wang Y, Luo X, Sun K, Wang H, et al. Prognostik signicnificance of plasma High-sensitivity C-reactive Protein in patients with hyperthropic cardiomyopathy. Am Heart Assoc. 2017;6: e004529
